Abstract
There is a large body of evidence indicating that inflammation plays a crucial role in all steps characterizing the atherosclerotic process. C-Reactive Protein is a circulating marker of inflammation which recently emerged as a powerful independent determinant of cardiovascular events. Hypertension is closely linked to inflammation. Experimental data and results from cross-sectional studies in humans indicate a relationship between CRP levels and blood pressure. In particular, CRP seems to be related with markers of arterial stiffness, thus suggesting a specific interaction between CRP and systolic blood pressure. However, such observational studies cannot provide any direct evidence for a cause-effect relation. Prospective studies are likely candidates to better define the putative causal relationship on this association. Available results from longitudinal studies are scanty, and do not allow to draw definitive conclusions. Moreover, prospective, placebo-controlled intervention trials documenting that reduction of CRP levels by pharmacological treatment might lead to a reduced risk to develop hypertension are not yet available. Without such crucial information, at the present time the causal connection between inflammation and blood pressure, although regarded as an intriguing possibility, remains undiscovered.
Keywords: C-reactive protein, inflammation, hypertension, cardiovascular risk
Current Pharmaceutical Design
Title: C-Reactive Protein and Hypertension: Is there A Causal Relationship?
Volume: 13 Issue: 16
Author(s): A. Virdis, L. Ghiadoni, Y. Plantinga, S. Taddei and A. Salvetti
Affiliation:
Keywords: C-reactive protein, inflammation, hypertension, cardiovascular risk
Abstract: There is a large body of evidence indicating that inflammation plays a crucial role in all steps characterizing the atherosclerotic process. C-Reactive Protein is a circulating marker of inflammation which recently emerged as a powerful independent determinant of cardiovascular events. Hypertension is closely linked to inflammation. Experimental data and results from cross-sectional studies in humans indicate a relationship between CRP levels and blood pressure. In particular, CRP seems to be related with markers of arterial stiffness, thus suggesting a specific interaction between CRP and systolic blood pressure. However, such observational studies cannot provide any direct evidence for a cause-effect relation. Prospective studies are likely candidates to better define the putative causal relationship on this association. Available results from longitudinal studies are scanty, and do not allow to draw definitive conclusions. Moreover, prospective, placebo-controlled intervention trials documenting that reduction of CRP levels by pharmacological treatment might lead to a reduced risk to develop hypertension are not yet available. Without such crucial information, at the present time the causal connection between inflammation and blood pressure, although regarded as an intriguing possibility, remains undiscovered.
Export Options
About this article
Cite this article as:
Virdis A., Ghiadoni L., Plantinga Y., Taddei S. and Salvetti A., C-Reactive Protein and Hypertension: Is there A Causal Relationship?, Current Pharmaceutical Design 2007; 13 (16) . https://dx.doi.org/10.2174/138161207780831365
| DOI https://dx.doi.org/10.2174/138161207780831365 |
Print ISSN 1381-6128 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Accelerating Cancer Drug Discovery Using Artificial Intelligence and In Silico Methods
Artificial intelligence and in silico methods speed up cancer drug discovery, transforming how new treatments are developed. Artificial intelligence, along with in silico methods, allows for quick investigation of large biological datasets, helping identify potential drug targets with remarkable speed and accuracy. Machine learning models help us understand how molecules ...read more
Artificial Intelligence and Computational Approaches in Drug Discovery
Computer-aided drug design (CADD) and artificial intelligence (AI) are fundamentally reshaping drug discovery pipelines by significantly enhancing efficiency in molecular screening, rational drug design, and natural product development. In the field of molecular screening, the integration of virtual high-throughput screening with advanced AI models enables rapid analysis of million-compound libraries, ...read more
Artificial Intelligence for Transformative Healthcare: From Prediction to Prevention
Machine learning and deep learning are transforming biomedical diagnosis by allowing for quicker and more accurate disease detection, ultimately enhancing patient care. Using advanced algorithms and extensive medical data, these approaches uncover patterns that may not be visible to humans, resulting in better detection of conditions such as cancer and ...read more
Mapping Dynamic Sites and Designing Novel Therapeutics
The concept of allostery, where ligand binding at a site distinct from the active or orthosteric site modulates protein function, has emerged as a transformative paradigm in modern drug discovery. Unlike conventional orthosteric drugs that often face limitations in selectivity and off-target effects, allosteric modulators offer a promising alternative. Their ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular Pharmacogenetics of Anti-Thrombotic Agents and Non-Steroidal Anti-Inflammatory Drugs
Current Molecular Medicine Drug Delivery Systems for Brain Tumor Therapy
Current Pharmaceutical Design Alzheimer’s Disease is Associated with Increased Risk of Osteoporosis: The Chongqing Aging Study
Current Alzheimer Research Effects of Obesity on Vascular Potassium Channels
Current Vascular Pharmacology Study of the Antihypertensive Effect of Laurus nobilis in Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Lycopene and Cardiovascular Diseases: An Update
Current Medicinal Chemistry Antenatal Maternal Antidepressants Drugs Affect S100B Concentrations in Fetal-Maternal Biological Fluids
CNS & Neurological Disorders - Drug Targets Somatostatin and its Analogs
Current Drug Targets Effects of <i>Piper sarmentosum</i> on Bone Health and Fracture Healing: A Scoping Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (Thematic Issue: Therapeutic Potential of microRNAs in Vascular Disease)
Current Vascular Pharmacology Childhood Systemic Lupus Erythematosus: New and Old Treatments
Current Pediatric Reviews <i>In Silico</i> Identification of Human miR-26a-1 from Hypertension Genome Sequence
Current Signal Transduction Therapy Targeted Renal Delivery of Protein Kinase Inhibitors for the Treatment of Chronic Kidney Disease
Current Signal Transduction Therapy Risk Factors for Nevirapine-Associated Rash Among HIV-Infected Patients with Low CD4 Cell Counts in Resource-Limited Settings
Current HIV Research Genetics of Congenital Heart Disease
Current Cardiology Reviews Pleiotropic, Cardioprotective Effects of Omega-3 Polyunsaturated Fatty Acids
Mini-Reviews in Medicinal Chemistry The Role of Mediterranean Diet, CoQ10 and Conjugated-Melatonin in Osteoporosis Primary Prevention and Therapy
Current Nutrition & Food Science Infection, Infectious Agents and Vascular Disease
Reviews on Recent Clinical Trials Antihypertensive Activity of Prunus armeniaca in Hypertensive Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Serum Uric Acid and Progression of Autosomal Dominant Polycystic Kidney Disease: Results from the HALT PKD Trials
Current Hypertension Reviews





